Table 1.
Association between MAPT haplotype, demographic factors, and pathological measures in PD patients
| Genotype | p value | ||
|---|---|---|---|
| H1/H1 | H2 | ||
| N= | 51 | 20 | |
| Male, N (%) | 37 (73) | 16 (80) | 0.76 |
| Age at death, mean (SD) | 76 (7) | 77 (8) | 0.87 |
| Disease durationa, years, mean (SD) | 18.4 (8.4) | 15.8 (9.7) | 0.54 |
| Braak LB stage | 0.10 | ||
| 4 | 7 (14 %) | 6 (30 %) | |
| 5 | 17 (33 %) | 7 (35 %) | |
| 6 | 27 (53 %) | 7 (35 %) | |
| CERAD scoreb | 0.39 | ||
| 0 | 22 (44 %) | 5 (26 %) | |
| A | 16 (32 %) | 8 (42 %) | |
| B | 5 (10 %) | 6 (32 %) | |
| C | 7 (14 %) | 0 | |
| Braak NFT stageb | 0.52 | ||
| 0 | 7 (14 %) | 0 | |
| I–II | 8 (16 %) | 3 (16 %) | |
| III–IV | 20 (40 %) | 12 (63 %) | |
| V–VI | 15 (30 %) | 4 (21 %) | |
Wilcoxon rank sum test was used to compare Braak LB stage, Braak NFT stage, and CERAD score between H1/H1 and H2 carriers. Fisher’s exact test was used to compare the gender, and a t test was used to compare age at death and disease duration
LB Lewy body, CERAD consortium to establish a registry for Alzheimer’s Disease, NFT neurofibrillary tangle
a
For disease duration, data were available for 18 H1/H1 and 6 H2 cases
b
For CERAD and NFT scores, 50 H1/H1 and 19 H2 cases were assessed